Dr. Jayson Parker is a teaching-stream faculty member in the Department of Biology at the University of Toronto Mississauga. He is appointed in the role of Medical Biotechnology Analyst at the University of Toronto. He lectures in the Master of Biotechnology Program, Faculty of Law and the Institute of Biomaterials and Biomedical Engineering. His main research interests include: biomarkers & clinical trial risk, machine learning, biotechnology patents and medical device regulation.
Dr. Parker is currently a medical/scientific advisor to the hedge fund Burlington Capital Inc, which has $25 million in assets under management and the Canadian Innovation Centre. He is also a board member for Life Sciences Ontario. Most recently, he was a medical liaison for Schering Plough’s biologic infliximab (Remicade) and for Novo Nordisk’s biologic rfVIIa (Novoseven/Niastase). He has been a “buy side” stock analyst covering the life sciences for Investor’s Group and the Director of Medical Science Equities at AIC limited (now Portland), both prominent mutual fund companies.
His research experience includes brain imaging of Alzheimer’s disease (Sunnybrook Hospital), animal models of alcohol abuse (Addiction Research Foundation) and animal models of schizophrenia (University of Toronto). His Doctoral work was on brain trauma (sensory map plasticity) and his Master’s research on cocaine addiction (reward pathways). During his MBA he focused on competitive intelligence issues in biotechnology.
Dr. Parker's recent publications are:
Chit A, J Parker, S Halperin, M Papadimitropoulos, M Krahn, and P Grootendorst. Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines.
Vaccine (in press).
Falconi A, Lopes G and J.L. Parker. Biomarker and Receptor Targeted therapies reduce Clinical Trial Risk in Non-Small Cell Lung Cancer.
Journal of Thoracic Oncology (in press)
Tenuta A, Klotz and J.L. Parker. Clinical Trial Risk in Castration Resistant Prostate Cancer: Immunotherapies Show Promise.
British Journal of Urology International (in press)
Parker JL, Lushina N, Bahl P, Petrella T, Dent R, and Lopez G. Impact of biomarkers on clinical trial risk in breast cancer.
Breast Cancer Research and Treatment 136:179-85, 2012
Jayasundara KS, Keystone EC and J L Parker. Risk of failure of a clinical drug trial in patients with moderate to severe rheumatoid arthritis.
Journal of Rheumatology 39:2066-70, 2012
Parker JL, Zhang ZY, and Buckstein R. Clinical trial risk in Non-Hodgkin’s lymphoma: Endpoint and target selection.
Journal of Pharmacy and Pharmaceutical Science. 14(2): 227-235. (2011)
Osborne BJW, Kaul R, Parker JL. Drug development risk in HIV-1 clinical trials: the effect of drug class.
Journal of Pharmaceutical Health Services Research 2: 211–216, 2011
Parker JL and Kohler JC. The success rate of new drug development in clinical trials: Crohn’s disease.
Journal of Pharmacy and Pharmaceutical Sciences.13(2): 191-197 (2010)
Reid, G.G.J., Bin Yameen, T.A. and J.L. Parker (in press) Impact of Biomarkers on Clinical Trial Risk.
Pharmacogenomics 14(13): 1 - XX.